1ZLB logo

Zai Lab DB:1ZLB Stock Report

Last Price

€2.60

Market Cap

€3.0b

7D

-6.5%

1Y

61.5%

Updated

27 May, 2025

Data

Company Financials +

Zai Lab Limited

DB:1ZLB Stock Report

Market Cap: €3.0b

1ZLB Stock Overview

A biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. More details

1ZLB fundamental analysis
Snowflake Score
Valuation3/6
Future Growth5/6
Past Performance0/6
Financial Health4/6
Dividends0/6

Rewards

Trading at 75.7% below our estimate of its fair value

Earnings are forecast to grow 64.06% per year

Earnings have grown 3.9% per year over the past 5 years

Risk Analysis

Volatile share price over the past 3 months compared to the German market


Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Zai Lab Limited Competitors

Price History & Performance

Summary of share price highs, lows and changes for Zai Lab
Historical stock prices
Current Share PriceUS$2.60
52 Week HighUS$3.64
52 Week LowUS$1.39
Beta1.04
1 Month Change-7.14%
3 Month Change-18.75%
1 Year Change61.49%
3 Year Change-7.14%
5 Year Changen/a
Change since IPO-80.45%

Recent News & Updates

Recent updates

Shareholder Returns

1ZLBDE BiotechsDE Market
7D-6.5%0.6%0.1%
1Y61.5%-12.7%16.4%

Return vs Industry: 1ZLB exceeded the German Biotechs industry which returned -12.9% over the past year.

Return vs Market: 1ZLB exceeded the German Market which returned 15.2% over the past year.

Price Volatility

Is 1ZLB's price volatile compared to industry and market?
1ZLB volatility
1ZLB Average Weekly Movement11.3%
Biotechs Industry Average Movement4.9%
Market Average Movement6.6%
10% most volatile stocks in DE Market12.9%
10% least volatile stocks in DE Market3.2%

Stable Share Price: 1ZLB's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: 1ZLB's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of German stocks.

About the Company

FoundedEmployeesCEOWebsite
20131,869Samantha Duwww.zailaboratory.com

Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company’s oncology pipeline includes bemarituzumab, tumor treating fields, tisotumab vedotin, and repotrectinib; and immunology, neuroscience, and infectious disease pipeline comprises efgartigimod and xanomeline and trospium chloride.

Zai Lab Limited Fundamentals Summary

How do Zai Lab's earnings and revenue compare to its market cap?
1ZLB fundamental statistics
Market cap€3.00b
Earnings (TTM)-€222.40m
Revenue (TTM)€369.09m
8.0x
P/S Ratio
-13.3x
P/E Ratio

Is 1ZLB overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1ZLB income statement (TTM)
RevenueUS$418.33m
Cost of RevenueUS$393.48m
Gross ProfitUS$24.85m
Other ExpensesUS$276.92m
Earnings-US$252.07m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)-2.32
Gross Margin5.94%
Net Profit Margin-60.26%
Debt/Equity Ratio21.4%

How did 1ZLB perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/27 08:43
End of Day Share Price 2025/05/27 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Zai Lab Limited is covered by 31 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael MengBOCI Research Ltd.
Wai Chak YuenBOCI Research Ltd.
Linda LuBOCI Research Ltd.